[SCHEDULE 13G] Tango Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Tango Therapeutics disclosed that Woodline Partners LP, acting as investment adviser to Woodline Master Fund LP, beneficially owns 6,029,906 shares of the company's common stock. That holding represents approximately 5.6% of the class based on an aggregate of 108,394,190 shares outstanding as reported in the company's quarterly report. The reporting party states it has sole voting and sole dispositive power over those shares.

The filing notes the shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The report identifies Woodline Partners as a Delaware limited partnership and names the Woodline Fund as the direct holder of the reported shares.

Positive

• Institutional ownership disclosed: Woodline Partners reports a material beneficial stake of 6,029,906 shares (~5.6%), indicating notable investor interest.
• Sole voting and dispositive power: The reporting person states sole authority to vote and dispose of the reported shares, clarifying control of the position.

Negative

• None.

Insights

Financial Analyst

TL;DR Woodline holds a material minority stake (5.6%) with sole voting and dispositive power; disclosure is material but non-directional.

The Schedule 13G reports a clearly defined beneficial position of 6,029,906 shares representing 5.6% of outstanding common stock, held directly by Woodline Master Fund LP and advised by Woodline Partners LP. The statement that the position is held in the ordinary course and not for the purpose of changing control limits immediate governance implications. For investors, the development signals institutional interest but contains no operational or strategic actions that would directly alter company fundamentals.

Corporate Governance Expert

TL;DR Institutional investor disclosed a >5% stake with sole authority; filing indicates passive intent rather than an activist approach.

The filing documents sole voting and dispositive power for the reported shares, which is important from a governance perspective because it confirms Woodline Partners can exercise control over voting of those shares unilaterally. However, the attestation that the shares are held in the ordinary course and not to influence control indicates no declared plan to pursue board or control actions. There is no indication of a group or shared power that would suggest coordinated governance activity.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

87583X109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87583X109

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,029,906.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,029,906.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,029,906.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tango Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Brookline Avenue, Suite 901, Boston, MA 02215
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Tango Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 108,394,190 shares of Common Stock outstanding as of May 5, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 12, 2025.
(b)	Percent of class: 5.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	08/14/2025

FAQ

How many Tango Therapeutics (TNGX) shares does Woodline Partners report owning?

Woodline Partners reports beneficial ownership of 6,029,906 shares of Tango Therapeutics common stock.

What percentage of Tango Therapeutics does the reported holding represent?

The reported holding represents approximately 5.6% of the outstanding common stock based on the company's reported share count.

Who holds the shares reported by Woodline Partners on Schedule 13G?

The shares are directly held by Woodline Master Fund LP, for which Woodline Partners LP serves as investment adviser.

Does Woodline Partners claim voting or dispositive control over the shares?

Yes. The filing discloses sole voting power and sole dispositive power over the 6,029,906 shares.

Is Woodline Partners seeking to influence control of Tango Therapeutics according to the filing?

The filing certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.